Market Research Logo

Global Lupus Nephritis Market: Industry Analysis & Outlook (2021-2030)

Global Lupus Nephritis Market: Industry Analysis & Outlook (2021-2030)

Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). Also called lupus, SLE is an autoimmune disease where the immune system turns against the body, affecting vital organs. While the primary cause of the disease is unknown, it is expected that factors such as viruses, infections, pollutants, and toxic chemicals, along with family history plays a role in causing the disease. The disease is more common in women compared to men. Kidney damage from lupus erythematosus can vary from mild to severe. In lupus nephritis, glomeruli or the filtering units are damaged. As a result, waste from the blood does not get filtered. Lupus nephritis happens when lupus involves the kidneys. When the kidneys are inflamed, they cannot function normally and can leak protein. If not controlled, lupus nephritis can lead to kidney failure.

The treatment for Lupus Nephritis is based upon on its type, which is determined by the biopsy. Since, symptoms and severity vary from person to person, treatments are individually tailored to meet a person's particular circumstances.

The global Lupus Nephritis market is set to experience favourable growth driven by factors such as increasing African-American population, rising health care expenditure and accelerating economic growth. The major trends observed in the market are new drugs under pipeline for Lupus Nephritis, increasing research grants with rising public awareness about the disease. However, the growth of this budding market will be hindered by stringent regulations, associated risk and high cost.

The report “Global Lupus Nephritis Market: Industry Analysis & Outlook (2021-2030)” analyses the development of this market, with focus on the U.S, Europe and Japan markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The five major players: Aurinia Pharmaceuticals Inc., Roche Holding AG, Bristol-Myers Squibb, GlaxoSmithKline Plc. and AstraZeneca are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global Lupus Nephritis market along with the study of the regional markets.


1. Overview
1.1 Introduction
Table 1: Systemic Lupus Erythematous (SLE) & Lupus Nephritis (LN) Overview
1.2 Symptoms
Table 2: Symptoms of Lupus Nephritis
1.3 Classification
Table 3: Classification of Lupus Nephritis (LN)
1.4 Treatment
Table 4: Voclosporin Commercial Opportunities
Table 5: Voclosporin Potential Benefits
Table 6: Development Stage of Voclosporin
2. Global Market Analysis
2.1 Global Lupus Nephritis Patient Population Forecast
Table 7: Global Lupus Nephritis Patient Population Forecast (2021-2030)
2.2 Global Lupus Nephritis Market Forecast by Value
Table 8: Global Lupus Nephritis Market Forecast by Value (2021-2030)
2.3 Global Lupus Nephritis Market by Region
Table 9: Global Lupus Nephritis Market by Region (2022/2030)
3. Regional Market Analysis
3.1 The U.S.
3.1.1 The U.S. SLE Patient Population Forecast
Table 10: The U.S. SLE Patient Population Forecast (2021-2030)
3.1.2 The U.S. Lupus Nephritis Patient Population Forecast
Table 11: The U.S. Lupus Nephritis Patient Population Forecast (2021-2030)
3.1.3 The U.S. Lupus Nephritis Market Forecast by Value
Table 12: The U.S. Lupus Nephritis Market Forecast by Value (2021-2030)
3.2 Europe
3.2.1 Europe Lupus Nephritis Patient Population Forecast
Table 13: Europe Lupus Nephritis Patient Population Forecast (2021-2030)
3.2.2 Europe Lupus Nephritis Market Forecast by Value
Table 14: Europe Lupus Nephritis Market Forecast by Value (2022-2030)
3.3 Japan
3.3.1 Japan Lupus Nephritis Patient Population Forecast
Table 15: Japan Lupus Nephritis Patient Population Forecast (2021-2030)
3.3.2 Japan Lupus Nephritis Market Forecast by Value
Table 16: Japan Lupus Nephritis Market Forecast by Value (2022-2030)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rise in African-American Population
Table 17: African-American Population (2012-2016
4.1.2 Accelerating Economic Growth
Table 18: Global GDP Per Capita (2012-2016)
4.1.3 Rising Health Care Expenditure
Table 19: Global Health Care Expenditure Per Capita (2012-2016)
4.1.4 Increasing Prevalence of Lupus Nephritis
4.2 Key Trends & Development
4.2.1 Drugs under Pipeline for Lupus Nephritis
Table 20: Active Drug Development Programs for Lupus Nephritis
4.2.2 Increasing Research Grants
4.2.3 Rising Public Awareness
4.3 Challenges
4.3.1 Stringent Regulations
4.3.2 Associated Risk
4.3.3 High Costs
Table 21: Annual Cost of Illness Per Patient by Disease (2016)
5. Competition
5.1 Global Market
5.1.1 Global Lupus Nephritis Market- Revenue Comparison of Key Companies
Table 22: Global Lupus Nephritis-Revenue Comparison of Key Companies (2016)
5.1.2 Global Lupus Nephritis Market- Market Cap Comparison of Key Companies
Table 23: Global Lupus Nephritis-Market Cap Comparison of Key Companies (2016)
6. Company Profiles
6.1 Aurinia Pharmaceuticals Inc.
6.1.1 Business Overview
Table 24: Aurinia Pharmaceuticals Inc. Revenue by Geographic Region (2016)
6.1.2 Financial Overview
Table 25: Aurinia Pharmaceuticals Revenue and Net Loss (2012-2016)
6.1.3 Business Strategies
6.2 Roche Holding AG
6.2.1 Business Overview
Table 26: Roche Holding AG Sales by Segments (2016)
6.2.2 Financial Overview
Table 27: Roche Holding AG Net Sales and Net Income (2012-2016)
6.2.3 Business Strategies
6.3 Bristol-Myers Squibb
6.3.1 Business Overview
Table 28: Bristol-Myers Squibb Revenue by Segments (2016)
6.3.2 Financial Overview
Table 29: Bristol-Myers Squibb Revenue and Net Earnings (2016)
6.3.3 Business Strategies
Table 30: Bristol-Myers Squibb Acquisitions (2016)
6.4 GlaxoSmithKline Plc.
6.4.1 Business Overview
Table 31: GlaxoSmithKline Plc. Revenue by Segments (2016)
6.4.2 Financial Overview
Table 32: GlaxoSmithKline Plc. Revenue and Net Profit (2012-2016)
6.4.3 Business Strategies
6.5 AstraZeneca
6.5.1 Business Overview
Table 33: AstraZeneca Revenue by Segments (2016)
6.5.2 Financial Overview
Table 34: AstraZeneca Revenue and Net Profit (2012-2016)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report